MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
Portfolio Pulse from
McKesson's Q3 fiscal 2025 results show growth in the U.S. Pharmaceutical segment, but overall earnings and sales missed expectations. The Medical Surgical Solutions segment was negatively impacted by lower COVID-related sales, leading to a contraction in gross margin.
February 06, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
McKesson's Q3 fiscal 2025 results missed earnings and sales expectations. The U.S. Pharmaceutical segment showed growth, but the Medical Surgical Solutions segment suffered due to lower COVID-related sales, leading to a contraction in gross margin.
The earnings and sales miss, along with the contraction in gross margin, are likely to negatively impact McKesson's stock price in the short term. The growth in the U.S. Pharmaceutical segment is a positive, but the negative impact on the Medical Surgical Solutions segment due to lower COVID-related sales is significant.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100